Camilla Hartmann Friis Hansen
- Laboratory animal science
- Gut microbiota research
- Experimental immunology
- Refinement of animal models of autoimmune, allergic, neurodevelopmental, and metabolic disorders
- External factors contributing to variation in disease expression. In particular, the importance of external factors regulating the gut environment during early life period of gestation and weaning that contribute to long-term influence on the hosts immune and metabolic systems is in focus, and how this may impact disease outcome and cause variation in animal models for human immune-mediated diseases.
- Improvement of mouse models for biomedical research. Humanizing mice by microbiota transplantations, trangenics, and stimulating microbiota-host interactions early in life.
- Discover mechanisms underlying perinatal health and disease in relation to delivery mode. My team aims to investigate the impact of cesarean section induced microbial perturbations on the development of the immune system in various animal models for chronic diseases.
In vivo models for biomedical research, germ-free and gnotobiotic mice, fecal microbiota transplantation, antibiotics, modified diets including pro-and prebiotics, cesarean sections, in vivo immunological characterisation. All used to study the impact of gut microbiota on model expression within lab animal science.
Possible conflicts of interest
- Collaborating with private enterprises, incl. Novo Nordisk A/S, Scanbur A/S, Glycom/DSM
- Obtained funding from private enterprises, incl. Novo Nordisk A/S
- Regular teaching on courses sponsored and organized by private companies, incl. Zealand pharma and Techniplast.